ITGAM and central nervous system cancer: Together, the findings presented here demonstrate profound remodeling of the immune landscape of the glioma TME after RGD + aPD-1 treatment, with a specific shift in the intratumoral reprogramming of infiltrating CD11b+CD45high myeloid populations, which results in augmented responses of CD8+ T cells.